Core Insights - ITM Isotope Technologies Munich SE and Radiopharm Theranostics have signed a supply agreement for non-carrier-added Lutetium-177 (n.c.a. Lu) to support Radiopharm's clinical and potential commercial development of Lu-based molecules [1][2] Company Overview - ITM is a leading radiopharmaceutical biotech company focused on developing therapeutics and diagnostics for hard-to-treat tumors, with a commitment to improving patient outcomes through high-quality radioisotopes [4] - Radiopharm Theranostics is a clinical-stage company developing innovative radiopharmaceutical products for diagnostic and therapeutic applications, with a pipeline that includes one Phase 2 and three Phase 1 trials targeting various solid tumors [5] Agreement Details - The supply agreement allows Radiopharm to utilize ITM's n.c.a. Lu in key clinical programs, including RAD 204, RAD 202, and RV01, aimed at treating solid tumors [2][3] - ITM's n.c.a. Lu is a highly pure beta-emitting radioisotope that can be linked to tumor-specific targeting molecules, enhancing the precision of cancer treatment [3] Strategic Importance - The agreement is seen as a critical step for Radiopharm to ensure the quality and reliability of its clinical development plans, particularly for its advanced assets [3] - ITM emphasizes its commitment to supplying high-quality medical radioisotopes to both its partners and its own pipeline, reflecting a shared dedication to improving cancer treatment options [4]